反应详情

Following a procedure analogous to that for the synthesis of Example 91, 2-(3-(butyl(3,4-dichlorobenzyl)carbamoyl)-4-chloro-5-methyl-1H-pyrazol-1-yl)-5-(8-(2-morpholinoethoxy)naphthalen-2-ylsulfonylcarbamoyl)benzoic acid (Intermediate 186B, 12 mg, 0.014 mmol) and (S)-(1,2,3,4-tetrahydroisoquinolin-3-yl)methanol (Aldrich, 9 mg, 0.056 mmol) were converted to the title compound (10 mg, 70%). 1H NMR (CD3OD, mixture of amide rotamers) δ 9.23-9.09 (m, 1H), 8.24 (dd, J=1.7, 8.0 Hz, 0.5H), 8.10-7.94 (m, 3.5H), 7.76-7.59 (m, 3H), 7.53-7.29 (m, 1.5H), 7.27-6.80 (m, 6H), 6.68 (d, J=7.5 Hz, 0.5H), 5.27-5.04 (m, 1H), 4.75-4.59 (m, 3H), 4.54-2.44 (m, 18H), 2.39-2.26 (m, 3H), 2.25-2.06 (m, 1H), 1.65-0.81 (m, 5.5H), 0.75-0.65 (m, 1H), 0.61-0.51 (m, 0.5H); MS(ESI+) m/z 1005.3 (M+H)+.